Ask AI
Test Your Skills: Biomarkers in NSCLC
Test Your Skills: The Importance of Biomarker Testing for Patients With Advanced NSCLC

Released: September 16, 2024

Activity

Progress
1 2
Course Completed

Follow-up—Impact of PD-L1 Expression on Treatment Selection
While waiting for molecular testing results, PD-L1 immunohistochemistry also was performed and showed that the tumor has high PD-L1 expression (tumor proportion score 50%).

How does high PD-L1 expression influence your treatment recommendation for this patient with an ALK rearrangement?